The publication summarizes knowledge of common omega-3 fatty acids like EPA and DHA, and in addtion how stearidonic acid, monounsaturated fatty acids, policosanols and astaxanthin can contribute to the metabolic and inflammatory health in a favorable way.
Head of Science in Calanus AS, Alice Marie Pedersen, PhD, says: “This publication is the first comprehensive review that evaluates the different bioactive constituents of Calanus® Oil. Even if there is still much to discover, there is already exisiting knowledge on for instance policosanols and monounsaturated fatty acids, which are associated with the mediterranean diet“.
The researchers also conclude that the the wax esters likely act as natural delayed release molecules, thereby facilitating transportation of fatty acids to the GPR120 receptors. The fatty acids act as potent stimulators of the GPR120 receptor, which is associated with reduced inflammation, improved insulin sensitivity and enhanced glucose uptake. GPR120 is a target for treatment of obesity and type 2 diabetes.
Dr. Pedersen concludes: „Stearidonic acid is also extremely interesting, and it is likely that this special fatty acid, as a part of the wax ester molecule, could explain many of the benefits we have observed in research and among consumers“.
Calanus® Oil is an omega-3 rich oil, where the fatty acid´s special chemistry gives additional benefits in the metabolic health area. Recent research has shown a favorable impact on body composition, insulin sensitivity and heart pumping efficiency. Calanus® Oil is currently being sold in Europe and North America, with several regualatory approval processes ongoing in other markets.
For further information, please contact Head of Sales and Marketing Jan Erik Olsen on tel. +47 951 45 351 or by e-mail: email@example.com. Please also refer to the company’s website: www.calanus.no.